Sunday, May 29, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Is COVID-19 vaccination during pregnancy safe?

by Medical Finance
in Coronavirus
Investigation: Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes. Image Credit: Marina Demidiuk / Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

A new retrospective cohort study conducted across a large population of pregnant women in Ontario, Canada, has confirmed that the coronavirus disease 2019 (COVID-19) vaccination administered during pregnancy is not associated with any increased risk of adverse maternal or neonatal peripartum outcomes.

The study, recently published in the journal JAMA, was conducted to compare individuals vaccinated after pregnancy to individuals with no vaccination record during or after pregnancy.

The findings remained unchanged when the data were stratified according to the number of doses received during pregnancy, vaccine manufacturer, or the trimester (second or third) when dose-1 was received.

Investigation: Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes. Image Credit: Marina Demidiuk / ShutterstockInvestigation: Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes. Image Credit: Marina Demidiuk / Shutterstock

Pregnancy and COVID-19

Women carrying pregnancy are at increased risk of COVID-19 related complications such as hospitalizations, intensive care units (ICU) admissions, and increased mortality risk. In addition, adverse pregnancy outcomes, such as premature births and stillbirths, have also been observed after severe acute respiratory syndrome coronavirus  2 (SARS-CoV-2) infection.

Like influenza and pertussis vaccines, which are routinely administered during pregnancy to protect both mother and newborns, many countries now recommend the COVID-19 vaccines during pregnancy. However, the relative lack of prelicensure safety data in pregnant women necessitates the need for more SARS-CoV-2 vaccine safety studies in this population to rule out any potential risks of adverse maternal or neonatal outcomes.

Previous studies indicate that COVID-19 vaccination during pregnancy is not associated with increased risks of spontaneous abortion, premature birth, or small-for-gestational-age birth. However, the evidence on other mother and newborn-related outcomes from large populations is still lacking.

The Study

The team evaluated maternal and neonatal peripartum outcomes, occurring just before, during, or after delivery, which could be associated with COVID-19 vaccination during pregnancy. Maternal outcomes included postpartum hemorrhage, chorioamnionitis, cesarean delivery, and emergency cesarean delivery, and newborn outcomes included neonatal ICU (NICU) admission and low newborn 5-minute Apgar score (<7).

This population-based retrospective cohort study was based on the pregnancy record data collected from Ontario (Canada) birth registry linked with the provincial COVID-19 immunization database. COVID-19 vaccination program began on December 14, 2020, in Ontario. Therefore, all pregnancy records with a birth date or expected due date on or after December 14, 2020, were probed until the end of the study period (September 30, 2021).

Linear and robust Poisson regression was used to analyze adjusted Risk Differences (aRDs) and adjusted Risk Ratios (aRRs) respectively, comparing cumulative incidence (CI) of outcomes in those who received COVID-19 vaccination during pregnancy with those vaccinated after pregnancy (comparison group-1) and those with no COVID-19 vaccination during or after pregnancy by September 30, 2021 (comparison group-2). Inverse probability of treatment weights was used to adjust for confounding factors.

Findings

Among 97,590 pregnant individuals from Ontario who met the study’s inclusion criteria, 23% (n=22,660) received at least one dose of COVID-19 vaccine during pregnancy and 77% (n=74,930) had not been vaccinated by delivery (46%/n=44,815 underwent after pregnancy [comparison group-1] and 31%/n=30,115 were not vaccinated by the end of study period [comparison group-2]).

Of the 22,660 individuals vaccinated during pregnancy, 3.4% received only dose 1; 48.3% received dose-1 during pregnancy and dose-2 after pregnancy; and 48.3% received both doses during pregnancy. Notably, 99.8% of pregnant individuals received an mRNA vaccine.

Compared with group-1, who received the COVID-19 vaccine after pregnancy, the team did not find any significant association between COVID-19 vaccination during pregnancy and postpartum hemorrhage. The cumulative incidence (CI) of postpartum hemorrhage in both groups was 3.0%, the aRR was 0.91 (95% CI, 0.82- 1.02), and the adjusted RD was −0.28 per 100 individuals (95% CI, −0.59 to 0.03).

Furthermore, COVID-19 vaccination during pregnancy (in comparison to group-1) was also not significantly associated with any increased risk of chorioamnionitis, cesarean delivery, NICU admissions, or Apgar score.

Compared with the group-2 individuals, who were never vaccinated, findings were qualitatively similar with no significantly increased risks of any of the outcomes in those vaccinated during pregnancy.

The results from sensitivity analyses, designed to account for potential confounding factors such as maternal age, calendar time, time since vaccination, gestational length, and COVID-19 during pregnancy, also did not vary from the original results.

“COVID-19 vaccination during pregnancy, compared with vaccination after pregnancy and with no vaccination, was not significantly associated with increased risk of adverse peripartum outcomes”, concludes the team.

 The team further cautions to interpret the study with the consideration that the vaccinations received during pregnancy were primarily mRNA vaccines administered in the second and third trimesters.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: “Never let a good crisis go to waste”: Positives from disrupted maternity care in Australia during COVID-19. Image Credit: Prostock-studio/Shutterstock

Positive effects of altered maternal care during COVID-19 in Australia

by Medical Finance
May 29, 2022
0

In a recent study published in Midwifery, researchers reported on the positive outcomes of the coronavirus disease 2019 (COVID-19) pandemic...

Study: Omicron infection enhances Delta antibody immunity in vaccinated persons. Image Credit: NIAID

SARS-CoV-2 Omicron infection boosts Delta immunity in those who have been vaccinated

by Medical Finance
May 29, 2022
0

The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) Omicron variant that was first identified in South Africa and Botswana in...

Study: T cell response following anti COVID-19 BNT162b2 vaccination is maintained against the SARS-CoV-2 Omicron B.1.1.529 variant of concern. Image Credit: natatravel/Shutterstock

Study finds stable T-Cell response against Omicron after mRNA booster vaccination

by Medical Finance
May 28, 2022
0

 Antibodies are critical when talking about protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated variants. However,...

Study: Enhanced SARS-CoV-2-Specific CD4+ T Cell Activation and Multifunctionality in Late Convalescent COVID-19 Individuals. Image Credit: Imilian / Shutterstock.com

CD4 T-cell immunity active six months into COVID-19 convalescence

by Medical Finance
May 28, 2022
0

The rollout of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen has led to a significant reduction...

Study: Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19. Image Credit: Noiel / Shutterstock

Prior COVID-19 protects against subsequent infections

by Medical Finance
May 28, 2022
0

In a recent study published in the Journal of American Medical Association (JAMA), researchers evaluated the duration and level of...

Study: Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity. Image Credit: Naeblys/Shutterstock

Study reveals Omicron sub-lineages BA.4 and BA.5 escape neutralizing antibodies elicited in response to BA.1 infection

by Medical Finance
May 28, 2022
0

In a recent study posted to the medRxiv* pre-print server, researchers evaluated whether neutralizing immunity elicited against Omicron sub-variant BA.1...

Next Post
‘Genetic scissors’ can give rise to unforeseen heritable mutations

Researchers report progress en route to developing a hypoallergenic cat

‘Forgetting’ may represent a form of learning, scientists say

New tissue-clearing method could speed the study of many disease-related biological processes

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: All-solid-state SARS-CoV-2 protein biosensor employing colloidal quantum dots-modified electrode. Image Credit: alphaspirit.it/Shutterstock
    SARS-CoV-2 protein biosensor employing colloidal quantum dots-modified electrode
  • Bronchitis 620x480
    Simple screening method could reduce the occurrence of lung diseases
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply